West Pharmaceutical Services (WST) Income towards Parent Company (2016 - 2026)
West Pharmaceutical Services has reported Income towards Parent Company over the past 18 years, most recently at $135.4 million for Q1 2026.
- Quarterly Income towards Parent Company rose 56.71% to $135.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $528.3 million through Mar 2026, up 16.52% year-over-year, with the annual reading at $479.3 million for FY2025, 0.27% changed from the prior year.
- Income towards Parent Company was $135.4 million for Q1 2026 at West Pharmaceutical Services, up from $128.2 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $183.0 million in Q2 2022 and troughed at $86.4 million in Q1 2025.
- The 5-year median for Income towards Parent Company is $132.1 million (2024), against an average of $131.4 million.
- Biggest five-year swings in Income towards Parent Company: crashed 32.43% in 2022 and later surged 56.71% in 2026.
- Tracing WST's Income towards Parent Company over 5 years: stood at $99.8 million in 2022, then skyrocketed by 33.97% to $133.7 million in 2023, then fell by 4.19% to $128.1 million in 2024, then grew by 0.08% to $128.2 million in 2025, then increased by 5.62% to $135.4 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods came in at $135.4 million, $128.2 million, and $137.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.